Last reviewed · How we verify
NCT04744857
Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve Replacement System With Retrievable Delivery Catheter System
NA trial testing The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system. in Aortic Stenosis in 85 participants. Completed in 16 October 2020.
16 October 2020
Quick facts
| Lead sponsor | Peijia Medical Technology (Suzhou) Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 85 |
| Start date | 13 December 2019 |
| Primary completion | 16 October 2020 |
| Estimated completion | 16 October 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- The experimental apparatus consisted of artificial aortic valve, transporter and grip-loading system.
Conditions studied
- Aortic Stenosis — all drugs for Aortic Stenosis →
Sponsor
Peijia Medical Technology (Suzhou) Co., Ltd.
Who can join
70 and older, any sex, with Aortic Stenosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The TaurusOne® transcatheter aortic valve system with retrievable delivery catheter system is evaluated the safety and effectiveness for the delivery of artificial aortic valve in a prospective, multicenter, single-arm clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04744857
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Stenosis
Currently open trials in the same condition.
- NCT07197736 — DELINEATE-Prospective · recruiting
- NCT07230964 — Correlation Between an Impedance Cardiography Test for Decompensation and the Development of Left Ventricular Replacemen · NA · recruiting
- NCT07205068 — Improved Outcomes With Pre-Procedure Shockwave IVL of Common Femoral Artery Access Site Prior to Large Bore Access and P · NA · recruiting
- NCT07052071 — Impact of Transcatheter Aortic Valve Implantation (TAVI) on the Gut Microbiota in Patients With Aortic Valve Stenosis · recruiting
- NCT07144189 — AI Assessment of Low-Gradient Aortic Stenosis Severity Based on Echocardiography · recruiting
Other Peijia Medical Technology (Suzhou) Co., Ltd. trials
Trials by the same sponsor.
- NCT06101888 — Safety and Effectiveness of TaurusTrio™ Heart Valve System in Patients With Severe Aortic Regurgitation (AR) · NA · recruiting
- NCT05655897 — Safety and Efficacy of the GeminiOne Transcatheter Valve Edge-to-Edge Repair System in Patients With Moderate-severe or · NA · recruiting
- NCT05610566 — Safety and Efficacy of the HighLife Transcatherter Mitral Valve Replacement System in Patients With Moderate-severe or S · NA · recruiting
- NCT04815785 — Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04744857 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peijia Medical Technology (Suzhou) Co., Ltd.
- Last refreshed: 21 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04744857.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing